Trinity Investors Celebrates Nuclein’s Dual FDA Clearance and CLIA Waiver for DASH® SARS-CoV-2 & Flu A/B Test
SOUTHLAKE, Texas, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Trinity Investors, a leading alternative asset management firm, proudly announces a significant milestone achieved by portfolio company Nuclein, LLC ...
Medindia10d
Nuclein Receives Dual FDA 510(k) Clearance and CLIA Waiver for DASH® SARS-CoV-2 & Flu A/B Test for use on the DASH® Rapid PCR System
"FDA 510(k) clearance and a CLIA waiver for the first of many anticipated tests for our DASH® Rapid PCR System marks an exciting step towards realizing this vision." Nuclein plans to begin ...
Medscape3 j
FDA Approves OraQuick for Use in Saliva
The Test: The OraQuick Rapid HIV-1/2 Antibody Test was originally approved for use in whole blood in November 2002 and received a CLIA waiver for expanded use in this setting in January 2003.
manilatimes7d
Trinity Investors Celebrates Nuclein's Dual FDA Clearance and CLIA Waiver for DASH® SARS-CoV-2 & Flu A/B Test
Nuclein has secured U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for its DASH® SARS-CoV-2 & Flu A/B Test, designed for use on ...